Could a menopause drug combo cut breast cancer risk?
NCT ID NCT04821141
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a daily pill combining bazedoxifene and conjugated estrogens can reduce breast cancer risk in 120 women aged 45-64 who have menopausal hot flashes and are at increased risk for breast cancer. Participants take the drug for 6 months or join a waitlist. Researchers measure changes in breast density and cell growth markers to see if risk may be lowered.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bazedoxifene plus conjugated estrogens (BZA+CE)
What this could lead to
If successful, this could point toward a hormone-based option to lower breast cancer risk in women with menopausal symptoms.
What could go wrong
This is a small, early-phase trial testing only biomarker changes, not actual cancer reduction. Results may not lead to a proven prevention method.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Northwestern Medical Center
Chicago, Illinois, 60601, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of California San Francisco
San Francisco, California, 94115, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States